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Abstract
Background: Although there is growing evidence that endocannabinoids play a critical role in
early pregnancy, there are no studies describing the possible targets for this system after
implantation. The endometrial stroma, which undergoes extensive proliferation and differentiation
giving rise to the decidua and the trophoblast cells that invade after the initial stages of implantation,
are potential targets. Since high anandamide (AEA) levels, the main endocannabinoid, are
detrimental to implantation and in order to gain insight into the role of the endocannabinoid system
in the development of the fetoplacental unit, the spatio-temporal pattern of expression of the
anandamide-binding receptors, CB1, CB2 and the vanilloid receptor (TRPV1), were investigated by
quantitative RT-PCR, western blot and immunohistochemistry.
Methods: Rat uterine maternal tissues from different days of pregnancy were used to investigate
the expression of CB1, CB2 and vanilloid receptors by quantitative RT-PCR, western blot and
immunohistochemistry.
Results: The data indicate that all the three receptors were expressed in decidualized cells and
placenta. Interestingly, CB1 and CB2 were also expressed in smooth muscle cells of maternal blood
vessels and in endovascular trophoblast cells, whereas TRPV1 was mainly expressed in uterine
natural killer (uNK) cells and in the longitudinal muscle layer throughout pregnancy. In all tissues,
CB2 protein was present at a lower level than CB1.
Conclusion: These observations support a role for the endocannabinoid system during the period
of decidualization and placental development.
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Background
Endocannabinoids are increasingly being recognised as
regulators of key cell-signalling pathways in female repro-
duction. These long-chain polyunsaturated fatty acid lipid
mediators mimic many of the effects of Δ9-tetrahydrocan-
nabinol (THC), the principal psychoactive compound of
marijuana, which has been reported to have adverse
effects on reproductive functions, including retarded
embryo development, fetal loss and pregnancy failure
[1,2]. N-arachidonoylethanolamine (anandamide, AEA)
and 2-arachidonylglycerol (2-AG) are the two main endo-
cannabinoids that have been characterized [3,4]. They are
not stored but produced by most tissues on demand via a
variety of stimuli that act on cannabinoid receptors, of
which CB1 and CB2 are the two main subtypes. CB1 and
CB2 are seven transmembrane G protein-coupled recep-
tors which on activation have different biological effects
that are cell-type specific and context-dependent [5,6]. It
has been shown that anandamide evokes a wide spectrum
of physiological actions, such as analgesia, vasodilatation,
cell proliferation and cell death, through these receptors
[7].
CB1 receptors were originally demonstrated in the central
nervous system, and CB2 was originally found to be
expressed in the spleen and immune cells [8,9]. Both
receptors are now known to be expressed at low levels in
tissues of the reproductive tract [10] and have been shown
to be functional in these tissues.
Anandamide has also been shown to have non CB1 and
non CB2-dependent effects suggesting the existence of a
CB3 receptor [11] and evidence exists that anandamide
can also bind to other receptors that are not exclusively
associated with cannabinoids [12]. Indeed, it has been
shown that anandamide binds to and activates the tran-
sient receptor potential vanilloid 1 receptor (TRPV1 or
VR1), which is characterized as a ligand-gated non selec-
tive cationic channel [13,14].
In the human, successful implantation and pregnancy
progression is characterized by low plasma levels of AEA,
while in labour the level of this endocannabinoid dramat-
ically increases [15]. Additionally, high levels of plasma
AEA in early pregnancy [16] or low fatty acid amide
hydrolase (FAAH) levels and activities [17] have been
shown to be associated with miscarriage. Low levels of
AEA have also been reported in the late luteal phase of the
menstrual cycle, coincident with the window of uterine
receptivity for implantation, supporting the importance
of the endocannabinoid system in early pregnancy [18].
In fact, endocannabinoid signalling is a critical pathway
in embryo-uterine cross-talk for successful blastocyst acti-
vation and implantation [19]. Low levels of AEA in the
receptive uterus and activated CB1 in blastocysts are ben-
eficial for implantation, whereas higher AEA levels are
detrimental to this process [20-22]. This dose-dependent
effect of AEA suggests a biphasic role for AEA in implanta-
tion and is further supported by findings showing that a
very narrow range of AEA concentrations regulate blasto-
cyst activation and implantation by differentially modu-
lating MAP kinase signalling and Ca2+ channel activity via
the CB1 receptor [19,23].
Following implantation, the uterus undergoes extensive
tissue remodelling, in order to achieve a successful preg-
nancy. In rodents, decidualization, which involves prolif-
eration and differentiation of the endometrial stromal
cells, starts in the vicinity of the implanting blastocyst giv-
ing rise to the antimesometrial decidua [24]. Thereafter,
decidualization expands to the opposite side of the uterus
(the mesometrial pole) to form the mesometrial decidua.
Development of this tissue is also associated with the
appearance of a third type of cell population, the uterine
natural killer cells (uNK), which have been implicated in
both successful pregnancy and pregnancy problems [25].
After full development, both decidual zones regress by
programmed cell death; however, not simultaneously,
suggesting that paracrine or autocrine mechanisms might
control apoptosis in specific regions of the decidua
[26,27]. These changes are considered to be crucial for
successful pregnancy but little is known about the molec-
ular mechanisms involved in these remodelling processes.
Since the endocannabinoid system has been suggested as
one of the key cytokine signalling pathways regulating
blastocyst maturation, oviductal transport, implantation
and maintenance of early pregnancy, we hypothesised
that important critical changes in this system in the mater-
nal component of the fetal-maternal interface would
occur during pregnancy. While endocannabinoid signal-
ling is clearly critical to early pregnancy events, effects in
the post implantation period and implications in preg-
nancy outcome remain unknown. Moreover, we have
recently shown the expression of both cannabinoid recep-
tors, as well as, TRPV1 in mesometrial decidual cells at day
10 of pregnancy. In addition, we also demonstrated the
involvement of CB1 receptor in decidual cell death [28].
However, it was not been described the presence of these
molecules after this day of pregnancy. Therefore, in order
to clarify the role of endocannabinoids it was investigated
the spatio-temporal pattern of expression of the cannabi-
noid receptors CB1 and CB2, as well as, of the related
receptor, TRPV1 throughout gestation.
Methods
Animals and tissue preparation
Nulliparous Wistar rats weighing 200-250 g (Charles
River Laboratories, Barcelona, Spain) were kept under
standard 12 h/12 h light/dark conditions in the laboratoryReproductive Biology and Endocrinology 2009, 7:121 http://www.rbej.com/content/7/1/121
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animal care facility of our institution. All procedures
involving animals were conducted in accordance with the
guidelines of the Ethics Committee of the Institute of
Molecular and Cellular Biology, Oporto University.
Female rats were mated with males and the day on which
spermatozoa were found in the morning vaginal smear
was designated day 1 of pregnancy. On days 8, 10, 12, 14,
16 and 19 of pregnancy, animals were sacrificed by cervi-
cal dislocation, and uteri were collected, fixed in 10% (v/
v) formal saline for 24 to 48 h and processed for routine
paraffin histology. The paraffin block was orientated to
enable the implantation sites to be sectioned transver-
sally. Serial sections (4 μm) through each implantation
site in the area containing the embryo were placed onto
slides coated with aminopropyl-triethoxysilane (Sigma
Chemical Co, St Louis, USA). Slides were dewaxed,
hydrated and stained with standard hematoxylin and
eosin to determine general tissue morphology and to
identify the different cell types present.
For the preparation of tissue homogenates, brain, spleen
and uterine horns, from day 10 until day 19 of pregnancy,
were dissected out and the maternal tissues separated
from placenta and homogenized with a Potter homoge-
nizer in a buffer consisting of 20 mM Hepes buffer, 2 mM
EDTA, 10 mM KCl, 1.5 mM MgCl2 (1:2) 1 mM phenyl-
methylsulphonylfluoride (PMSF) and aprotinin (1:100).
The homogenates were centrifuged at 700 g for 10 min at
4°C to remove cell membranes and nuclei. The superna-
tants were then centrifuged at 12000 g for 30 min at 4°C
and the supernatants stored at -80°C. The amount of pro-
tein was measured by the Bradford assay kit (Bio-Rad,
Laboratories Melville, NY, USA).
For RT-PCR analyses, 100 mg of tissue was homogenised
directly in homogenisation buffer (Qiagen RNAEasy kit;
Qiagen, Hilden, Germany) and the RNA purified through
Qiagen columns according to the manufacturer's instruc-
tions. The RNA was eluted in 30 μl of RNAse-free water
and stored at -80°C for later RT-PCR analysis.
Quantitative RT-PCR analysis
RNA was quantified spectrophometrically at 260 and 280
nm and RNA quality assessed using ethidium-stained aga-
rose gels. RNA with a 260/280 ratio of 1.8 and above was
reverse-transcribed using avian myelomablastosis reverse
transcriptase (Promega Corp. Southampton, UK) as previ-
ously described [29]. For quantitative PCR, gene specific
primers (Table 1) were used at 10 pmol/μl in a SYBR green
system (Roche Diagnostics, Lewes, UK) with 1 μl of cDNA
as template in a Roche Lightcycler 1.2. The PCR condi-
tions in all cases started with a denaturation step at 95°C
for 10 min and followed by up to 50 cycles of denatura-
tion, annealing and primer extension (Table 1). Standard
curves of diluted cDNA pools were constructed for each
gene target and the expression levels corrected for the lev-
els of rat β-actin using the 2-ΔΔCt method [30] and normal-
ised to the ratio produced from the day 10 of pregnancy
sample.
Western blot analysis
Homogenized samples were resolved by electrophoresis
on a 10% SDS-polyacrylamide gel. The separated proteins
were transferred onto a nitrocellulose membrane in 25
mM Tris-HCl, 250 mM glycine, 20% methanol (v/v), pH
8.3, for 2 h at 200 V. The membranes were incubated with
a 1:100 dilution of polyclonal antibodies against CB1 (sc-
20754), CB2 (sc-25494) or TRPV1 (sc-12498) from Santa
Cruz Biotechnology (Santa Cruz, CA, USA) in blocking
solution overnight at 4°C. Membranes were exposed to X-
ray film (Kodak XAR; Eastman Kodak, Rochester, NY,
USA) and bands were visualized by chemiluminescence
Table 1: Primer sequences, gene accession number and Q-PCR conditions.
mRNA target GenBank accession No. Primers Conditions Ref.
-actin 95°C, 15 sec Cintado et al., 2001
NM_031144 Sense 5'-CCTAGCACCATGAAGATCAA-3' 60°C, 20 sec
Antisense 5'-TTTCTGCGCAAGTTAGGTTTT-3' 72°C, 30 sec
Cb1 NM_012784 95°C, 20 sec Porcella et al., 1998
Sense 5'-CATCATCATCCACACGTCAG-3' 60°C, 30 sec
Antisense 5'-ATGCTGTTGTCTAGAGGCTG-3' 72°C, 20 sec
Cb2 NM_020543 95°C, 20 sec Porcella et al., 1998
Sense 5'-TTTCCCACTGATCCCTAACG-3' 60°C, 30 sec
Antisense 5'-AGTTAACAAGGCACAGCATG-3' 72°C, 20 sec
Trpv1 AF237067 95°C, 25 sec Dvorakova et al., 2001
Sense 5'-TGGAACAACGGGCTAGCTTA-3' 58°C, 30 sec
Antisense 5'-TCCTCATAAGGGCAGTCCAG-3' 72°C, 25 sec
CB1, cannabinoid receptor 1; CB2, cannabinoid receptor 2; TRPV1, transient receptor potential vanilloid 1 receptorReproductive Biology and Endocrinology 2009, 7:121 http://www.rbej.com/content/7/1/121
Page 4 of 13
(page number not for citation purposes)
(Super Signal West Pico; Pierce, Rockford, USA). The sig-
nal intensity was quantified by densitometry (BIO-PRO-
FIL Bio-1D++, Vilber Lourmat, France). Homogenates of
brain and spleen were used as positive controls for CB1,
TRPV1 and CB2, respectively. Membranes were then
stripped and incubated with anti-β-tubulin (1:500)
(Santa Cruz, CA, USA) antibody to control loading varia-
tions. A total of four animals were used for all the experi-
ments.
Immunohistochemistry
Expression of CB1, CB2, and TRPV1 was analyzed using
an avidin-biotin alkaline phosphatase complex immuno-
histochemical technique (Vectastain ABC kit, Vector Lab-
oratories, CA, USA). After dewaxing, rehydration and
blocking of non-specific binding sites, slides were incu-
bated, overnight with the primary antibodies rabbit anti-
CB1 and anti-CB2 (1:100) and goat anti-TRPV1 (1:100) at
4°C. After washing with PBS they were incubated with
diluted biotinylated secondary antibody for 30 min, fol-
lowed by incubation with Vectastain ABC-AP reagent, as
recommended in the kit instructions. The reaction was
developed by incubation with Sigma Fast Red tablets
(Sigma Chemical Co, St Louis, USA). Negative controls
were performed with the inclusion of rabbit or goat IgG
instead of the CB1/CB2 or TRPV1 primary antibodies. The
slides were counterstained with Mayer's hematoxylin
solution (Sigma Diagnostics, St Louis, USA) and mounted
in Aquamount improved medium (BDH Laboratory Sup-
plies, Poole, England). In each experimental immunohis-
tochemical run, sections from all days of pregnancy (days
8 to 19) were included and a total of three implantation
sites from five different animals were used for all the
experiments.
Statistical analysis
Statistical analysis was performed using one-way ANOVA,
followed by the Bonferroni post-hoc test to make pairwise
comparisons of individual means (GraphPad PRISM ver-
sion 4.0, GraphPad Software, Inc., San Diego, CA, USA)
when significance was indicated. All numerical data are
expressed as mean ± SEM and differences were considered
to be statistically significant at p < 0.05.
Results
CB1, CB2 and TRPV1 mRNA levels
Figure 1 shows the relative levels of transcripts for CB1,
CB2 and TRPV1 in the uterine maternal tissues from day
10 to day 19 of pregnancy. While for CB1 and TPVR1 a
trend to increase on day 12 was detected, for CB2 this ten-
dency was observed on day 10 and 14. The pattern of tran-
script expression for CB1 and TRPV1 was similar.
However, the differences in transcript levels for all three
receptors were not significantly different between the days
of gestation.
Western blot analysis
The relative abundance of CB1, CB2 and TRPV1 protein in
the mesometrial decidua throughout pregnancy was also
evaluated by immunoblotting (Figure 2). In contrast to
the transcript levels, there were significant differences in
the protein levels of the receptors between days of gesta-
tion. CB1 protein levels on day 12 were significantly (p <
0.05) higher than those on days 16 and 19 of pregnancy
(Figure 2A, B). CB2 was also expressed in the mesometrial
decidua throughout the period in study, however, the
absolute protein levels appeared to be less than that
shown by CB1. In contrast to CB1, there were no statisti-
cally significant differences in the protein levels for CB2
(Figure 2A, C). TRPV1 was also present in all days of preg-
nancy, and after day 14 declined towards the end of gesta-
tion, being the protein levels significantly (p < 0.05)
Anandamide binding receptor transcript levels during pregnancy Figure 1
Anandamide binding receptor transcript levels during pregnancy. The levels of transcripts for (A) CB1, (B) CB2 and 
(C) TRPV1 were measured by Q-PCR and normalised against rat β-actin levels. The data were then divided by the mean value 
obtained on Day 10 and presented as mean ± SEM; n = 4.Reproductive Biology and Endocrinology 2009, 7:121 http://www.rbej.com/content/7/1/121
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elevated on day 12 when compared to the end of gestation
(Figure 2A, D).
Expression pattern of CB1, CB2 and TRPV1 receptor - 
Days 8 to 10 of pregnancy
Since only significant variations between days of preg-
nancy were found at the protein level, the spatio-temporal
pattern of CB1, CB2 and TRPV1 expression was investi-
gated by immunohistochemistry.
Decidualized cells of the antimesometrium exhibited a
high expression for CB1 receptor compared with that for
CB2 (Figure 3A, B, C). Although TRPV1 was positive in the
antimesometrial decidua on days 8 and 10, the expression
was more intense in the vicinity of the embryo (Figure
3E). In the antimesometrial pole, near the circular muscle
coat, the fibrinoid capsula, a layer of closely packed cells
adjacent to the undifferentiated endometrium [31], was
negative for all three receptors (Figure 3A, C).
The mesometrial decidual cells started to show immuno-
positivity for both cannabinoid receptors by day 10 (Fig-
ure 4A, B), although again CB2 staining was less intense
when compared to that for CB1. In addition, a few small
round cells, the precursors of uterine NK cells, which
appear later in the mesometrial triangle and in the mes-
ometrial decidua, expressed CB1 (Figure 4B). The smooth
muscle cells of blood vessels exhibited immunopositivity
for CB1 and CB2 (data not shown). Only a few decidual
cells of the mesometrium and the uNK cells began to
express TRPV1 on day 10 (Figure 4C). No signal was
detected in the smooth muscle cells of the blood vessels
Anandamide-binding receptor protein levels in mesometrial decidua during pregnancy Figure 2
Anandamide-binding receptor protein levels in mesometrial decidua during pregnancy. (A) Representative west-
ern blots for CB1, CB2, TRPV1 and β-tubulin of protein extracts from mesometrial decidua taken on days 10, 12, 14, 16 and 19 
of pregnancy. Brain homogenates were used as positive controls (control) for CB1, TRPV1 and spleen homogenates for CB2. 
β-tubulin was used as a loading control. (B) Densitometric analysis of CB1, CB2 (C) and TRPV1 (D) protein levels. The differ-
ent protein levels were normalized to the level of β-tubulin. Bar graphs show the mean of experiments carried out with four 
different animals. Results are depicted as means ± SEM. Data labelled with different letters are significantly different from each 
other.Reproductive Biology and Endocrinology 2009, 7:121 http://www.rbej.com/content/7/1/121
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Immunohistochemical demonstration of anandamide-binding receptor expression in the rat uterus on day 8 of pregnancy Figure 3
Immunohistochemical demonstration of anandamide-binding receptor expression in the rat uterus on day 8 of 
pregnancy. (A) CB1 expression is evenly distributed in the antimesometrial decidua; (B) Higher magnification of the square 
indicated in (A); (C) CB2 expression in decidual cells of antimesometrium, note that CB2 staining appears to be less intense 
than CB1; (D) A negative control for CB2 of a consecutive section of (C); (E) TRPV1 expression; note a higher expression in 
the cells close to the embryo; (F) TRPV1 expression in longitudinal and circular muscle layers. AMD - Antimesometrial 
decidua; CM - Circular muscle layer; Ec - Embryonic cells; FC - Fibrinoid capsule; LM - Longitudinal muscle layer.Reproductive Biology and Endocrinology 2009, 7:121 http://www.rbej.com/content/7/1/121
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for this receptor. Circular and longitudinal muscle layers
presented an intense signal for TRPV1 on day 8 and 10
(Figure 3F).
Spatiotemporal expression of CB1, CB2 and TRPV1 
receptor - Days 12 to 14 of pregnancy
On day 12, the decidual cells near to the early placenta
called the ectoplacental cone, showed immunopositivity
for CB1 (Figure 5A). CB2 was also present, but expressed
with a lower intensity, though with the same pattern to
that of CB1. On day 12, CB1 was first detected in the tro-
phoblast cells of the ectoplacental cone (Figure 5A) and in
the endovascular trophoblast cells (Figure 5B). Immunos-
taining for CB1 was detected in the smooth muscle cells of
the blood vessels (Figure 5C). Immunopositive staining
for both receptors was observed in the metrial gland,
localized to uNK cells (Figure 5C).
On day 14, the expression of immunoreactive CB1 and
CB2 was found in all mesometrial decidual cells and in
the placenta (giant trophoblast and spongiotrophoblastic
cells) (Figure 6A, C, D). On this day, the endothelial cells
were also positive for CB1 (Figure 6A, B).
TRPV1 immunoreactivity in the mesometrial decidua
increased in intensity in the decidual cells and in uNK
cells from days 12 to 14 (Figure 5D, 6F). There was strong
immunoreactivity for this receptor in the uNK cells of the
Immunohistochemical demonstration of anandamide-binding receptors expression in uterus on day 10 of pregnancy Figure 4
Immunohistochemical demonstration of anandamide-binding receptors expression in uterus on day 10 of 
pregnancy. (A) CB1 expression in the decidualized cells in the mesometrium pole; (B) Higher magnification of the square indi-
cated in (A) showing positive staining in precursors of uNK cells (arrows); (C) TRPV1 expression in the mesometrial pole in 
uNK cells (arrows); (D) A negative control for CB1. BV - Blood vessel; MD - Mesometrial decidua.Reproductive Biology and Endocrinology 2009, 7:121 http://www.rbej.com/content/7/1/121
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metrial gland (Figure 6G, H). Contrary to what was found
for CB1, the endovascular trophoblast cells were negative
for TRPV1 (Figure 6G). A very weak signal was observed in
the circular compared to the longitudinal smooth muscle
layer. Within placental cells, TRPV1 immunoreactivity
was confined to the giant cells and to a few spongiotro-
phoblast cells (Figure 6F).
Spatiotemporal expression of CB1, CB2 and TRPV1 
receptor protein - Days 16 to 19 of pregnancy
Expression of CB1 was predominantly localized in the
regressing mesometrial decidua (Figure 7A) and contin-
ued to be expressed in the placenta. On day 19, the expres-
sion of both cannabinoid receptors were unchanged
compared to day 16. On day 19, TRPV1 continued to be
CB1 and TRPV1 immunoreactivity on day 12 of pregnancy Figure 5
CB1 and TRPV1 immunoreactivity on day 12 of pregnancy. (A) CB1 expression in decidualized cells in the mesome-
trial region; note that positive staining was restricted to the edges of mesometrial decidua nearest to the ectoplacental cone, 
which also is positive for CB1; (B) Expression of CB1 in the endovascular trophoblast cells; (C) Expression of CB1 in the 
metrial gland. Smooth muscle cells of blood vessels and uNK cells (arrows) are positive; (D) TRPV1 expression in decidualized 
cells in the mesometrial region in the vicinity of ectoplacental cone, which show some positivity. BV - Blood vessel; EC - Ecto-
placental cone; MD - Mesometrial decidua; MG - Metrial gland.Reproductive Biology and Endocrinology 2009, 7:121 http://www.rbej.com/content/7/1/121
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Spatial distribution of cannabinoid and vanilloid receptors on day 14 of pregnancy Figure 6
Spatial distribution of cannabinoid and vanilloid receptors on day 14 of pregnancy. (A) CB1 expression, in the mes-
ometrial decidua and basal zone of placenta; (B) High magnification of the square depicted in (A); note the positive decidual and 
endothelial cells. (C) Higher magnification image of the basal zone. The giant trophoblast and spongiotrophoblast cells are pos-
itive for CB1; (D) Expression of CB2 is lower than CB1 in the mesometrial decidua and basal zone; (E) Negative control for 
TRPV1; (F) TRPV1 expression in the mesometrial decidua and basal zone; (G) High magnification of the mesometrial decidua 
and endovascular trophoblast cells; note the lack of staining for TRPV1 in these trophoblast cells and the presence of apoptotic 
bodies in the decidua (arrowheads); (H) Expression of TRPV1 is particularly evident in uNK cells in the metrial gland region 
(arrows). BV - Blood vessel; BZ - Basal zone; ET - Endovascular trophoblast cells; GT - Giant trophoblast cells; MD - Mesome-
trial decidua; MG - Metrial gland; ST - Spongiotrophoblast cells.Reproductive Biology and Endocrinology 2009, 7:121 http://www.rbej.com/content/7/1/121
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expressed in the uNK cells and also in the longitudinal
smooth muscle layer (Figure 7B, C, D).
Discussion
Although the endocannabinoid system has been investi-
gated at the time of implantation in the endometrium of
the mouse model [21], there are to our knowledge no
studies that have investigated this system in the post-
implantation period. The widespread expression of can-
nabinoid receptors in numerous organs suggested that
endocannabinoids might have functions other than psy-
choactive. For example, evidence has emerged to support
a role for the endocannabinoid system in blastocyst devel-
opment and implantation following the localisation of
Spatial distribution of CB1 and TRPV1 in the uterus on day 16 and 19 of pregnancy Figure 7
Spatial distribution of CB1 and TRPV1 in the uterus on day 16 and 19 of pregnancy. (A) On day 16, decidual and 
trophoblast cells from the basal zone are positive for CB1. Note the lack of expression in circular and longitudinal muscle layer; 
(B) In the metrial gland, the expression of TRPV1 at day 19 is mainly localized in uNK cells and in longitudinal muscle layer. (C) 
High power of the square depicted in (B). Expression of TRPV1 is particularly evident in uNK cells (arrows). (D) High power 
showing an intense positive signal for TRPV1 in the longitudinal muscle layer. BV - Blood vessel; BZ - Basal zone; CM- Circular 
muscle layer; LM - Longitudinal muscle layer; MD - Mesometrial decidua; MG - Metrial gland.Reproductive Biology and Endocrinology 2009, 7:121 http://www.rbej.com/content/7/1/121
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the cannabinoid receptors, CB1 and CB2, to the blastocyst
and to the uterus during the peri-implantation period
[20,32,33].
We used Q-PCR and western blot to demonstrate tran-
script and protein levels throughout pregnancy for the
anandamide-binding receptors CB1, CB2 and TRPV1, and
uterine tissue, distribution of these receptors was revealed
by immunohistochemistry.
In the rat and other mammals, including the human,
fibroblast-like endometrial stromal cells undergo syn-
chronized proliferation and differentiation in response to
the implanting blastocyst, a phenomenon designated as
decidualization [24]. In the rat, after proliferation, the
decidual tissue goes through a cycle of regression, which
begins at day 10 in the antimesometrium side and contin-
ues, in the mesometrium pole, until the end of pregnancy
[26,27]. This biological programming of endometrial
stromal fibroblasts into decidual cells is thought to be
affected by locally released factors produced by maternal
tissues and blastocyst [31,34,35]. Though the exact mech-
anisms controlling this process in normal pregnancy are
unknown, they may be related to the endocannabinoid
system [36].
Immunohistochemistry revealed that CB1 is expressed
mainly in decidual cells throughout gestation suggesting
that an action mediated by CB1 is not only associated
with implantation [19], but also with the maintenance of
pregnancy. Our western blot results showed that CB1 was
upregulated during midpregnancy, being ~1.5-fold higher
on day 12, which is not in accordance with Q-PCR data,
suggesting that the expression of proteins is transcription-
unregulated. In fact, the uterine remodelling is a dynamic
and highly regulated process associated with the synthesis
of different types of molecules, like growth factors and
hormones. These molecules may be critical for the regula-
tion of the translational process, what explain the differ-
ences observed between Q-PCR and western blot results.
After day 12, when maximum development of the mes-
ometrium decidua occurs, the decidualization process is
completed and the mesometrial decidual cells undergo
apoptosis [27]. By contrast, by day 12 of gestation the
antimesometrium has already undergone regression.
During the period up to day 10 the fibroblast stromal cells
of this region proliferate and differentiate, whereas by day
12 only a few cells remain. Indeed, the expression levels of
CB1 is higher on the antimesometrium side on day 10
suggesting that CB1 may be involved in the programmed
cell death that occurs in this period in the antimes-
ometrium. Moreover, Kessler et al. showed that a CB1 ago-
nist inhibits human decidualization and stimulates
apoptosis by a cAMP-dependent mechanism [36] indicat-
ing that anandamide signals or initiates apoptosis. In
addition, we have shown the involvement of anandamide
in mesometrial decidual cell death through CB1, suggest-
ing a role for this receptor in decidual regression [28].
Although CB2 was first isolated from immune cells with
particularly high levels in B lymphocytes and natural
killer cells [37], little is known about the physiological
role of this receptor. In this work, CB2 presented a similar
expression pattern to CB1, though with less intensity and
without significant differences throughout pregnancy as
revealed by western blot analysis. It is possible that CB2
might contribute to the control of cytokine networks
responsible for maternal/fetal cross talk.
Buckley et al. described CB1 and CB2 receptor mRNAs in
the outer longitudinal layer and in the inner circular layer
of myometrium of the pregnant rat uterus [38]. However,
it was detected immunoreactivity for all the receptors in
the circular muscle layer, with decreasing intensity as ges-
tation advances. This raises the possibility that these
receptors may play a role in myometrial contractility,
though a direct effect of AEA and THC as relaxants on
human myometrium contractility in vitro, mediated
through CB1, has been described [39]. Conversely, we
also detected a strong reactivity for the vanilloid receptor
in the longitudinal muscle layer throughout gestation.
These data demonstrate differential regulation of TRPV1
expression between the muscle layers that would result in
enhancement of relaxation activity in the longitudinal
muscle of the gravid horn during pregnancy, necessary to
achieve embryo development and parturition. In the
human, a dramatic increase in plasma anandamide levels
during labour at term compared with non-labouring
women has been described [15] suggesting a role for
anandamide in labour. Thus, we hypothesise that TRPV1
activation mediated by anandamide might contribute to
the ability of the outer myometrial layer to generate opti-
mal contractile activity during labour. In the same way,
AEA may induce vasodilatation in vascular tissues, which
appears to be mediated through the CB1 receptor [40,41].
Our study also demonstrated that cannabinoid receptor
expression, mainly CB1, in the smooth muscle cells of
blood vessels occurs until day 12 of pregnancy, suggesting
that anandamide, acting through the vascular CB1, may
be involved in the vasodilatation which is crucial for the
development of a normal pregnancy. In addition, ananda-
mide produces vasorelaxation in different vascular beds in
an endothelium-dependent and endothelium-independ-
ent manner [10]. We found expression of CB1 in endothe-
lial cells from day 12 until the end of pregnancy and
although anandamide has been shown to exert some of its
effects directly on vascular smooth muscle via the CB1
receptor [42], a direct action of anandamide on the
endothelium is also possible.Reproductive Biology and Endocrinology 2009, 7:121 http://www.rbej.com/content/7/1/121
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The presence of immunoreactive TRPV1 in uNK cells was
observed from day 10 until degranulation, contrary to
CB1 expression that diminishes around day 12. The dis-
tinctive expression of TRPV1 and the loss of CB1 expres-
sion could be related to the induction of the apoptosis
that occurs in these cells during this period [27], as has
been suggested for other cell types [43].
In human pregnancy, cannabinoid receptor expression
has been detected in first trimester placental tissues
[16,44] and at term [33]. Our results also revealed expres-
sion of CB1 in the rat endovascular trophoblast, giant tro-
phoblast and spongiotrophoblast cells, suggesting that
CB1 might be involved in trophoblasts-associated uterine
remodelling mechanisms. Moreover, as TRPV1 was pri-
marily found in giant trophoblast cells, activation of this
receptor may counter-balance the trophoblast invasion.
Conclusion
All these data indicate that a tightly regulated level of
endocannabinoids is crucial during placental develop-
ment. The differential spatio-temporal expression pat-
terns of the cannabinoid and vanilloid receptors suggest
that there is an uncoupling of these two types of ananda-
mide-binding receptors in mid/late gestation that are
related to changes in cell phenotype. The reasons for this
are not clear, but it may be explained by a differential role
for anandamide in the various cell types, which may also
be dose-dependent. To our knowledge, this is the first
study providing direct evidence of the existence of anan-
damide-binding receptors in uterine tissues throughout
pregnancy and for supporting a role for the endocannabi-
noid system during the period of placental development.
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